Number of the records: 1  

Novel strategies for enhanced fluorescence visualization of glioblastoma tumors based on HPMA copolymers conjugated with tumor targeting and/or cell-penetrating peptides

  1. 1.
    0587174 - ÚMCH 2025 RIV CN eng J - Journal Article
    Grosmanová, Eliška - Pola, Robert - Filipová, Marcela - Henry, M. - Coll, J.-L. - Etrych, Tomáš
    Novel strategies for enhanced fluorescence visualization of glioblastoma tumors based on HPMA copolymers conjugated with tumor targeting and/or cell-penetrating peptides.
    View. Roč. 5, č. 3 (2024), č. článku 20230116. ISSN 2688-3988. E-ISSN 2585-8793
    R&D Projects: GA ČR(CZ) GA22-12483S; GA MZd(CZ) NU21-08-00280; GA MŠMT LX22NPO5102
    Institutional support: RVO:61389013
    Keywords : cell-penetrating peptides * diagnostics * HPMA copolymers
    OECD category: Polymer science
    Impact factor: 9.7, year: 2023
    Method of publishing: Open access
    https://onlinelibrary.wiley.com/doi/10.1002/VIW.20230116

    Nano-sized polymer systems are often used as carriers for drugs and contrast agents to increase circulation time and solubility and to reduce possible side effects. These nanomedicines usually accumulate in tumor tissue due to the enhanced permeability and retention (EPR) effect. However, a targeting group may be attached to the polymer carrier in addition to the active substance to further increase tumor accumulation and specificity. In this study, the oligopeptide sequence RGD was chosen to target αvβ3 integrins overexpressed in the tumor vasculature and on some tumor cells. A set of polymer conjugates bearing a fluorescent dye and RGD peptide of different structures (linear, cyclic, branched) was prepared for use in tumor diagnosis, with a potential future application in navigated surgery. The accumulation of the most promising candidate, a targeted fluorescent nanoprobe, increased by 35% in glioblastoma tumors compared to the non-targeted control, which accumulated only due to the EPR effect. However, the administration of a polymer-bound modified cilengitide as an antiangiogenic treatment did not show a beneficial effect in the suppression of angiogenesis.
    Permanent Link: https://hdl.handle.net/11104/0354500

     
    FileDownloadSizeCommentaryVersionAccess
    0587174.pdf02.6 MBLicense CC BY 4.0Publisher’s postprintopen-access
     
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.